98%
921
2 minutes
20
The rational design of receptor agonists to control cell signaling is an emerging strategy for developing disease therapeutics. Creating a soluble cytokine-like agonist for the Notch receptor, which regulates cell fate in embryonic and adult development, is challenging, as receptor activation requires a mechanical force that is usually mediated by cell-associated transmembrane ligands. Here, we exploit computationally designed protein complexes with precise valencies and geometries to generate soluble cytokine-like Notch agonists. These molecules promote cell-cell bridging, cluster Notch receptors at cell synapses, and activate receptor signaling. We show that these agonists drive T cell differentiation from cord blood progenitors and human induced pluripotent stem cells (iPSCs) and in bioreactor production of T cells in liquid suspension. When delivered intravenously in mice, they stimulate cytokine production, expansion of antigen-specific CD4 T cells, and antibody class switching. These de-novo-designed ligands can be broadly applied to optimize in vitro cell differentiation and advance immunotherapy development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327808 | PMC |
http://dx.doi.org/10.1016/j.cell.2025.07.009 | DOI Listing |
Stem Cell Res Ther
September 2025
Department of ORL-HNS, Shanghai Fourth People's Hospital, and School of Medicine, Tongji University, Shanghai, China.
Background: The united airway diseases (UADs), exemplified by allergic rhinitis and asthma, cause significant morbidity. Although conventional pharmacotherapy provides symptomatic relief, recent evidence has indicated that cellular therapy, such as stem cell-derived exosomes, might offer therapeutic advantages throughout the entire respiratory tract.
Objectives: The present study intends to demonstrate the effect and explore the mechanism of a novel pharmaco-exosomal immunotherapy, i.
Front Immunol
August 2025
Department of Diagnostic Sciences, Ghent University and Ghent University Hospital, Ghent, Belgium.
Introduction: The Gardasil-4 vaccine targets HPV types 6, 11, 16 and 18 and is formulated with amorphous alum. Cervarix targets HPV types 16 and 18 using AS04 (Al(OH)3 + TLR4 agonist MPL) to enhance immune response. Cervarix elicits higher cross-protection against other high-risk HPV types, likely mediated by AS04.
View Article and Find Full Text PDFCell
July 2025
Stem Cell & Regenerative Biology Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA. E
The rational design of receptor agonists to control cell signaling is an emerging strategy for developing disease therapeutics. Creating a soluble cytokine-like agonist for the Notch receptor, which regulates cell fate in embryonic and adult development, is challenging, as receptor activation requires a mechanical force that is usually mediated by cell-associated transmembrane ligands. Here, we exploit computationally designed protein complexes with precise valencies and geometries to generate soluble cytokine-like Notch agonists.
View Article and Find Full Text PDFJ Ovarian Res
July 2025
Department of Vascular Surgery, Quzhou People's Hospital, No. 100, Minjiang Avenue, Kecheng District, Quzhou, 324000, Zhejiang, China.
Background: Notch2 and Wnt2/β-catenin pathway improve granulosa cell (GC) functions, and there are interactions between Notch and Wnt/β-catenin in some cells. We aimed to investigate whether Notch2 improves GC functions in premature ovarian failure (POF) by activating the Wnt2/β-catenin pathway.
Methods: Notch2 expression was interfered in mice or KGN cells, then, mice were treated with cyclophosphamide and busulfan intraperitoneally, and KGN cells were exposed to cyclophosphamide to establish POF models.